This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ buflomedil hydrochloride,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Peripheral Vascular Diseases: Buflomedil hydrochloride is indicated for the treatment of peripheral arterial occlusive diseases (PAOD) and intermittent claudication. It works by dilating blood vessels, particularly arterioles and capillaries, thereby improving blood circulation to the limbs. This can help alleviate symptoms such as pain, cramping, and weakness during physical activity.

  2. Intermittent Claudication: Intermittent claudication is a symptom of peripheral arterial disease characterized by pain or cramping in the legs during physical activity due to inadequate blood flow. Buflomedil hydrochloride helps increase blood flow to the affected limbs, reducing symptoms and improving exercise tolerance in individuals with intermittent claudication.

  3. Vasodilation: Buflomedil hydrochloride exerts its therapeutic effects by acting as a vasodilator, relaxing smooth muscle cells in blood vessel walls and widening the diameter of blood vessels. This vasodilatory action enhances blood flow and oxygen delivery to tissues, particularly in areas with impaired circulation.

  4. Tissue Oxygenation: By improving blood flow and oxygen delivery to peripheral tissues, buflomedil hydrochloride may help promote tissue healing and reduce the risk of complications associated with peripheral vascular diseases, such as ischemic ulcers and gangrene.

  5. Symptom Relief: Buflomedil hydrochloride can alleviate symptoms associated with peripheral vascular diseases, including leg pain, numbness, tingling, and cold extremities. By enhancing blood flow, it may improve patients' quality of life and functional status.

  6. Adverse Effects: Common side effects of buflomedil hydrochloride may include gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), headache, dizziness, flushing, and palpitations. These side effects are usually mild and transient.

  7. Contraindications: Buflomedil hydrochloride is contraindicated in patients with hypersensitivity to the drug or its components. It should be used with caution in individuals with severe hepatic impairment, as hepatic metabolism plays a role in the elimination of buflomedil.

  8. Drug Interactions: Buflomedil hydrochloride may interact with other medications, including antihypertensive agents and vasodilators, potentially leading to additive hypotensive effects. Healthcare providers should review patients' medication regimens to minimize the risk of drug interactions.

  9. Pregnancy and Lactation: The safety of buflomedil hydrochloride during pregnancy and breastfeeding has not been established. It should only be used in pregnant or lactating women if the potential benefits outweigh the risks and under the supervision of a healthcare provider.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of buflomedil hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by buflomedil hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Bacteroides genus Decreases
0 1 Escherichia genus Decreases
1 0 Akkermansia genus Decreases
0 1 Shigella genus Decreases
0 1 Lachnospira genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Clostridium genus Decreases
0 1 Escherichia coli O1:K1:H7 no rank Decreases
0 1 Escherichia coli O139:H1 no rank Decreases
0 1 Escherichia coli O141:H4 no rank Decreases
0 1 Escherichia coli O145:H34 no rank Decreases
0 1 Escherichia coli O15:H12 no rank Decreases
0 1 Escherichia coli O155:H21 no rank Decreases
0 1 Escherichia coli O158:H23 no rank Decreases
0 1 Escherichia coli O16:H48 no rank Decreases
0 1 Escherichia coli O170:H18 no rank Decreases
0 1 Escherichia coli O18ac:H14 no rank Decreases
0 1 Escherichia coli O19:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H4 no rank Decreases
0 1 Escherichia coli O2:K1:H5 no rank Decreases
0 1 Escherichia coli O2:K1:H7 no rank Decreases
0 1 Escherichia coli O20:H12 no rank Decreases
0 1 Escherichia coli O25:H16 no rank Decreases
0 1 Escherichia coli O55:H7 no rank Decreases
0 1 Escherichia coli O68:H12 no rank Decreases
0 1 Escherichia coli O7:H15 no rank Decreases
0 1 Escherichia coli O78:H51 no rank Decreases
0 1 Escherichia coli O80:H26 no rank Decreases
0 1 Escherichia coli O84:H7 no rank Decreases
0 1 Escherichia coli O85:H1 no rank Decreases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
0 1 Escherichia coli O103 serogroup Decreases
0 1 Escherichia coli O111 serogroup Decreases
0 1 Escherichia coli O119 serogroup Decreases
0 1 Escherichia coli O121 serogroup Decreases
0 1 Escherichia coli O145 serogroup Decreases
0 1 Escherichia coli O155 serogroup Decreases
0 1 Escherichia coli O157 serogroup Decreases
0 1 Escherichia coli O177 serogroup Decreases
0 1 Escherichia coli O26 serogroup Decreases
0 1 Escherichia coli O3 serogroup Decreases
0 1 Escherichia coli O43 serogroup Decreases
0 1 Escherichia coli O5 serogroup Decreases
0 1 Escherichia coli O78 serogroup Decreases
0 1 Escherichia coli O86 serogroup Decreases
0 1 Escherichia coli O91 serogroup Decreases
0 1 Escherichia coli H20 serotype Decreases
0 1 Escherichia coli O1:H42 serotype Decreases
0 1 Escherichia coli O1:HNT serotype Decreases
0 1 Escherichia coli O10:H32 serotype Decreases
0 1 Escherichia coli O10:K5(L):H4 serotype Decreases
0 1 Escherichia coli O100:H21 serotype Decreases
0 1 Escherichia coli O103:H11 serotype Decreases
0 1 Escherichia coli O103:H2 serotype Decreases
0 1 Escherichia coli O103:H25 serotype Decreases
0 1 Escherichia coli O104:H21 serotype Decreases
0 1 Escherichia coli O104:H4 serotype Decreases
0 1 Escherichia coli O111:H- serotype Decreases
0 1 Escherichia coli O111:H11 serotype Decreases
0 1 Escherichia coli O111:H8 serotype Decreases
0 1 Escherichia coli O111:NM serotype Decreases
0 1 Escherichia coli O112ab:H8 serotype Decreases
0 1 Escherichia coli O112ac:H19 serotype Decreases
0 1 Escherichia coli O113:H21 serotype Decreases
0 1 Escherichia coli O114:H49 serotype Decreases
0 1 Escherichia coli O118:H16 serotype Decreases
0 1 Escherichia coli O121:H19 serotype Decreases
0 1 Escherichia coli O121:H7 serotype Decreases
0 1 Escherichia coli O123:H11 serotype Decreases
0 1 Escherichia coli O125ac:K+:H10 serotype Decreases
0 1 Escherichia coli O126:H45 serotype Decreases
0 1 Escherichia coli O127:H27 serotype Decreases
0 1 Escherichia coli O127:H6 serotype Decreases
0 1 Escherichia coli O128:H2 serotype Decreases
0 1 Escherichia coli O128ac:H12 serotype Decreases
0 1 Escherichia coli O139:H28 serotype Decreases
0 1 Escherichia coli O145:H25 serotype Decreases
0 1 Escherichia coli O145:H28 serotype Decreases
0 1 Escherichia coli O145:NM serotype Decreases
0 1 Escherichia coli O146:H21 serotype Decreases
0 1 Escherichia coli O15:H18 serotype Decreases
0 1 Escherichia coli O150:H6 serotype Decreases
0 1 Escherichia coli O152:H23 serotype Decreases
0 1 Escherichia coli O153:H2 serotype Decreases
0 1 Escherichia coli O156:H25 serotype Decreases
0 1 Escherichia coli O157:H- serotype Decreases
0 1 Escherichia coli O157:H43 serotype Decreases
0 1 Escherichia coli O157:H7 serotype Decreases
0 1 Escherichia coli O157:NM serotype Decreases
0 1 Escherichia coli O16:H6 serotype Decreases
0 1 Escherichia coli O165:H25 serotype Decreases
0 1 Escherichia coli O167:H26 serotype Decreases
0 1 Escherichia coli O174:H2 serotype Decreases
0 1 Escherichia coli O174:H21 serotype Decreases
0 1 Escherichia coli O174:H8 serotype Decreases
0 1 Escherichia coli O176:H45 serotype Decreases
0 1 Escherichia coli O177:NM serotype Decreases
0 1 Escherichia coli O2:H6 serotype Decreases
0 1 Escherichia coli O2:K2:H1 serotype Decreases
0 1 Escherichia coli O25:H1 serotype Decreases
0 1 Escherichia coli O25:NM serotype Decreases
0 1 Escherichia coli O26:H1 serotype Decreases
0 1 Escherichia coli O26:H11 serotype Decreases
0 1 Escherichia coli O28ac:NM serotype Decreases
0 1 Escherichia coli O29:H4 serotype Decreases
0 1 Escherichia coli O32:H37 serotype Decreases
0 1 Escherichia coli O39:NM serotype Decreases
0 1 Escherichia coli O44:H18 serotype Decreases
0 1 Escherichia coli O45:H2 serotype Decreases
0 1 Escherichia coli O6:H16 serotype Decreases
0 1 Escherichia coli O6:H16:CFA/II serotype Decreases
0 1 Escherichia coli O6:K2:H1 serotype Decreases
0 1 Escherichia coli O69:H11 serotype Decreases
0 1 Escherichia coli O7:H4 serotype Decreases
0 1 Escherichia coli O7:K1 serotype Decreases
0 1 Escherichia coli O78:H12 serotype Decreases
0 1 Escherichia coli O78:H4 serotype Decreases
0 1 Escherichia coli O79:H7 serotype Decreases
0 1 Escherichia coli O8:H8 serotype Decreases
0 1 Escherichia coli O81:NM serotype Decreases
0 1 Escherichia coli O83:H1 serotype Decreases
0 1 Escherichia coli O86:H34 serotype Decreases
0 1 Escherichia coli O89m:H10 serotype Decreases
0 1 Escherichia coli O89m:H9 serotype Decreases
0 1 Escherichia coli O9:H10 serotype Decreases
0 1 Escherichia coli O91:H14 serotype Decreases
0 1 Escherichia coli O91:NM serotype Decreases
0 1 Escherichia coli O99:H6 serotype Decreases
0 1 Escherichia coli ONT:H33 serotype Decreases
1 0 Bacteroides caccae species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Escherichia coli species Decreases
1 0 Akkermansia muciniphila species Decreases
0 1 Bacteroides luhongzhouii species Decreases
0 1 Bacteroides sp. DH3716P species Decreases
1 0 Lachnospira eligens species Decreases
0 1 Shigella dysenteriae species Decreases
0 1 Shigella flexneri species Decreases
0 1 Bacteroides faecium species Decreases
0 1 Escherichia albertii species Decreases
1 0 Thomasclavelia ramosa species Decreases
0 1 Escherichia fergusonii species Decreases
0 1 Bacteroides caecimuris species Decreases
0 1 Shigella boydii species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
0 1 Bacteroides ovatus species Decreases
0 1 Bacteroides sp. D2 species Decreases
0 1 Bacteroides sp. M10 species Decreases
0 1 Shigella sonnei species Decreases
0 1 Escherichia marmotae species Decreases
0 1 Escherichia sp. E4742 species Decreases
1 0 [Ruminococcus] torques species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
1 0 Clostridium perfringens species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of buflomedil hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.2 0.2
Allergic Rhinitis (Hay Fever) 0.6 0.7 -0.17
Allergies 1.1 0.9 0.22
Allergy to milk products 1.2 0.6 1
Alzheimer's disease 1.4 1.6 -0.14
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.2 0.8 0.5
Ankylosing spondylitis 1.5 0.4 2.75
Anorexia Nervosa 0 0.4 0
Antiphospholipid syndrome (APS) 0.5 0.5
Asthma 0.9 0.9 0
Atherosclerosis 0.8 0.2 3
Atrial fibrillation 0.4 0.7 -0.75
Autism 1.4 2.1 -0.5
Autoimmune Disease 0.4 0 0
benign prostatic hyperplasia 0.4 0.3 0.33
Biofilm 0.5 0.5
Bipolar Disorder 0.7 0.7
Brain Trauma 0.3 -0.3
Breast Cancer 0.5 0.5
Cancer (General) 0.8 -0.8
Carcinoma 0.6 0.3 1
Celiac Disease 0.8 0.6 0.33
Cerebral Palsy 0.5 0.3 0.67
Chronic Fatigue Syndrome 1 0.3 2.33
Chronic Kidney Disease 1.5 0.4 2.75
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.5 0.1 4
Chronic Urticaria (Hives) 0.7 0.4 0.75
Coagulation / Micro clot triggering bacteria 0.9 0.9
Cognitive Function 0.3 0 0
Colorectal Cancer 1.8 0.8 1.25
Constipation 0.8 0.8
Coronary artery disease 0.9 0.3 2
COVID-19 2 2.1 -0.05
Crohn's Disease 1.6 1.2 0.33
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.7 0.3 1.33
d-lactic acidosis (one form of brain fog) 0.5 0.5
deep vein thrombosis 1.1 0.3 2.67
Depression 2.5 1.6 0.56
Eczema 0.4 0 0
Endometriosis 1.2 0.6 1
Epilepsy 1.4 0.9 0.56
erectile dysfunction 0.7 0.7
Fibromyalgia 0.2 0.3 -0.5
Functional constipation / chronic idiopathic constipation 1.5 1.1 0.36
gallstone disease (gsd) 0.7 0.2 2.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 -0.1
Generalized anxiety disorder 1.4 0.5 1.8
giant cell arteritis 0 0
Gout 1.8 0.3 5
Graves' disease 0.3 0.3 0
Gulf War Syndrome 0 0.5 0
Halitosis 0.3 0.3
Hashimoto's thyroiditis 0.6 0.7 -0.17
Heart Failure 1.5 0.2 6.5
Hidradenitis Suppurativa 0.4 0.4
High Histamine/low DAO 0.5 0.5
hypercholesterolemia (High Cholesterol) 0.5 0.4 0.25
hyperglycemia 1 0.9 0.11
Hyperlipidemia (High Blood Fats) 0.2 0.2
hypertension (High Blood Pressure 1.5 0.7 1.14
Hypothyroidism 0.2 0.2
Hypoxia 0.5 0.5
IgA nephropathy (IgAN) 0.3 0.4 -0.33
Inflammatory Bowel Disease 2.2 1.5 0.47
Insomnia 0.3 1.2 -3
Intelligence 0.8 0.8
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 2.5 1.1 1.27
ischemic stroke 0.8 0.7 0.14
Liver Cirrhosis 1.2 1.4 -0.17
Long COVID 1.7 0.9 0.89
Low bone mineral density 0.1 -0.1
Lung Cancer 1.1 0.4 1.75
Lymphoma 0.4 0.4
Mast Cell Issues / mastitis 0.4 0.4
ME/CFS with IBS 0 0.3 0
ME/CFS without IBS 0 0.3 0
Menopause 0.2 0.2 0
Metabolic Syndrome 2 0.9 1.22
Mood Disorders 2.3 1.6 0.44
multiple chemical sensitivity [MCS] 0.2 0.2
Multiple Sclerosis 1 0.6 0.67
Multiple system atrophy (MSA) 0.5 0.5
myasthenia gravis 0.4 0 0
neuropathic pain 0.6 -0.6
Neuropathy (all types) 0.2 0.2 0
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.7 1 0.7
NonCeliac Gluten Sensitivity 0.7 0.3 1.33
Obesity 2.7 1.2 1.25
obsessive-compulsive disorder 1.3 0.8 0.63
Osteoarthritis 0.8 0.5 0.6
Osteoporosis 0.7 0.7 0
Parkinson's Disease 1.9 0.9 1.11
Polycystic ovary syndrome 0.7 0.5 0.4
Postural orthostatic tachycardia syndrome 0 0
primary biliary cholangitis 0 0
Primary sclerosing cholangitis 0.3 0 0
Psoriasis 0.7 0.7 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1 0.3 2.33
Rosacea 0.1 0 0
Schizophrenia 0.8 0.6 0.33
scoliosis 0.5 0.2 1.5
Sjögren syndrome 0.4 0.3 0.33
Sleep Apnea 0.2 0.3 -0.5
Slow gastric motility / Gastroparesis 0.8 0.8
Small Intestinal Bacterial Overgrowth (SIBO) 0.8 0.8
Stress / posttraumatic stress disorder 1.2 0.7 0.71
Systemic Lupus Erythematosus 0.7 0.1 6
Tourette syndrome 0.2 0.3 -0.5
Type 1 Diabetes 1.2 0.4 2
Type 2 Diabetes 2 1.4 0.43
Ulcerative colitis 1.7 1 0.7
Unhealthy Ageing 0.4 0.2 1
Vitiligo 0.4 0.2 1

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]